Navigation Links
LMS Third Quarter 2008 Financial Results - Q3 Revenue Increases 88% to $1.0 Million - YTD Revenue Increases 87% to $2.6 Million
Date:2/12/2008

007.

Cash, cash equivalents and short-term investments held to maturity, as at December 31, 2007 totaled $0.5 million compared to $3.38 million as at March 31, 2007. In addition, under our contract with a distributor, LMS is entitled to receive amounts for contracts contained in our backlog, described below. As at December 31, 2007, this amount, which does not qualify as a receivable under generally accepted accounting principles, amounted to $0.6 million and will provide short term additional liquidity. As such, the total cash, cash equivalents, short term investments and accounts receivable, including this amount, amounted to $1.8 million as at December 31, 2007.

THIRD QUARTER HIGHLIGHTS:

- In conjunction with a seasonally stronger spring quarter (Q4) and

corporate streamlining of operations, we anticipate reaching a cash

flow break even for the last quarter of the current fiscal year.

- Both the backlog of signed contracts and identified sales opportunities

were maintained at $4.6 million and $25 million, respectively.

- In total, we added six new hospitals to our client base as well as four

insurance contracts during the third quarter of fiscal 2008.

- We implemented a program to streamline operations, thus substantially

reducing LMS expenses with the objective of reaching near term positive

cash flow and ensuring profitability. There are reductions in

consulting expenses and salaries in research and development and other

non core expenditures. All operational, sales and core development

activities have been maintained. Also, management has demonstrated its

commitment to the future of LMS by making a collective decision to

temporarily suspend a portion of salaried compensation for the balance

of fiscal 2008. Upon meeting certain milestones, the board of directors

will have an option to pay the suspended salarie
'/>"/>

SOURCE LMS MEDICAL SYSTEMS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag
2. Haemacure Reports Third Quarter 2007 Results
3. Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. Martek Announces Third Quarter 2007 Financial Results
6. MDS Reports Third Quarter 2007 Results
7. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
8. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
9. Webcast Alert: Heska Announces Third Quarter 2007 Earnings Conference Call Webcast
10. AABB and Fenwal Sponsor Third Annual Blood Collectors Week
11. Brookdale Announces Third Quarter Common Stock Dividend of $0.50
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...S, N.J., Nov. 21 Today, ...l intervention in treating 88 percent of patients ...mericans treated for a chronic condition account f...d 75 percent of all medical costs. A proprietary ...edco Health Solutions, Inc. (NYSE: MHS ) signifi...
(Date:11/21/2008)... popular drugs do not cause genetic damage that ca...ealthDay News) -- Two popular medications for trea...D) do not cause genetic damage linked to an increa..., The study, done by researchers at Duke Univer... Health, counters a previous one that reported bio...
(Date:11/21/2008)..., a new and deadly diseaseits cause remains a myst...was teeming with citizens, soldiers and refugees o...s streets filled with corpses, social order broke ...ned twice and Athens lost a third of its populatio...d the beginning of the end of the Golden Age of Gr...
(Date:11/21/2008).... 21 /PRNewswire/ -- For the second year in a r...Cann Healthcare Worldwide,s agency network won mor... the 22nd annual international RX Club Show. , ...ices won a total of 59 RX Club Awards of Excellenc...Cann Healthcare Worldwide agencies include Caudex ...
Breaking Medicine News(10 mins):Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4
...anderbilt University Medical Center reveal a surpr...rt that the Golgi apparatus -- a stack of pancake... out to their cellular destinations -- is the sour...icroscopic fibers. Scientists have long thought t...
...sorder figures among seem to soar out of proportio...published in response to parliamentary questions ... children being hospitalized with eating disorders...cade. This mainly comprises of people under the ag...
... and women seeking surgical procedures among most ...oration procedures were performed worldwide in 200...cs released today from a recent member survey cond...ation Surgery (ISHRS) -- the world's leading medic...
...rnment took a step Wednesday toward offering vacci... as 12, a measure that could be carried out by la...and Immunisation (JCVI) recommended the use of vac... (HPV), a sexually transmitted infection which cau...
Other Medicine News:Health News:Research in the Origin of Microtubules 2Health News:Research in the Origin of Microtubules 3Health News:Eating Disorder Figures Among Children Soars 2Health News:Hair Restoration Procedures Performed Worldwide Increased 34 Percent in 2006 2Health News:Hair Restoration Procedures Performed Worldwide Increased 34 Percent in 2006 3Health News:Girls Could Be Vaccinated Against Cervical Cancer in Britain 2
(Date:11/20/2008)...ewswire/ -- Milk. It does a body good. And,now it...fter years of,research, scientists at OncoNutriti...lk that stimulate the body,s own production of ant...s Release, go to:, http://www.prnewswire.com/mnr/e...ew cancer therapies, the chief scientist, Dr. Davi...
(Date:11/20/2008)...-- Clinical data from a prospective,registry pres... shows DVT,treatment with the Trellis(R) Peripher...anta Clara, CA) successfully breaks up the blood c... This technique, called isolated pharmacomechanic... and safely than current catheter-directed thrombo...
(Date:11/19/2008)... Amgen,(Nasdaq: AMGN )...bsidiary of,Takeda Pharmaceutical Company Limited...the Phase 3 MONET1 trial evaluating motesanib (AMG...tin for the first-line treatment of,advanced non-...y suspended,following a planned safety data revie...
(Date:11/19/2008)...re/ -- Isogen, a contract development and,manufac...ounced the first,phase launch of its contract fac...ally address the process, facility and capacity pr...ghly-niched, low-volume clinical and,early-stage ... Companies can invest over $100 million and four ...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2BioMarin Announces First Quarter 2008 Financial Results 4955 1BioMarin Announces First Quarter 2008 Financial Results 4955 2BioMarin Announces First Quarter 2008 Financial Results 4955 3BioMarin Announces First Quarter 2008 Financial Results 4955 4BioMarin Announces First Quarter 2008 Financial Results 4955 5BioMarin Announces First Quarter 2008 Financial Results 4955 6BioMarin Announces First Quarter 2008 Financial Results 4955 7BioMarin Announces First Quarter 2008 Financial Results 4955 8BioMarin Announces First Quarter 2008 Financial Results 4955 9BioMarin Announces First Quarter 2008 Financial Results 4955 10BioMarin Announces First Quarter 2008 Financial Results 4955 11Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 1Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 2Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 3Nephros Appoints Gerald J Kochanski as Chief Financial Officer 4951 4Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 1Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases 1932 2Engineers harness cell phone technology for use in medical imaging 4950 1Engineers harness cell phone technology for use in medical imaging 4950 2Engineers harness cell phone technology for use in medical imaging 4950 3Engineers harness cell phone technology for use in medical imaging 4950 4
... THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 30, 2...esults from a pivotal Phase 3,trial which showed t...clonal antibody directed against the epidermal gro...free survival (PFS) compared,to best supportive ca...who had failed fluoropyrimidine, irinotecan, and,o...
... ROCHESTER, N.Y., May 02, 2007 /PRNewswire/ -- A ... before last winter may have been,less effective t...adults who had flu shots before last winter were o...se who were not vaccinated. The,differences were l...ic.(1) In the winters of 2003/2004 and 2004/2005 a...
Other Medicine Technology:Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 2Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 3Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 4Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 5Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published 6Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 2Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 3Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 4Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 5Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than,Vaccines Used in Previous Years 6
It provides excellent illumination from an inexpensive platform and is mounted on the comfortable UltraLite headband.
A rapid rise in intracranial pressure requires early recognition, intervention and continuous monitoring. Ventrix utilizes state-of-the-art fiberoptic technology that gets to the source of pressure.
The Codman ICP Monitoring System provides highly accurate measurements of intracranial pressure at the source-subdural, parenchymal or intraventricular levels. The information is relayed electronical
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)
Medicine Products: